LOS ANGELES, November 20, 2024--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA™-Breast1) Phase II ...
Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of aurora kinase A, for breast cancer treatment. In this trial, alisertib will be ...
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic ...
Football — or as some may call it, soccer — has become an important sport for athletic apparel and footwear brands to grasp onto in order to expand into becoming staple lifestyle brands in the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback